4988 related articles for article (PubMed ID: 22397650)
1. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Gerlinger M; Rowan AJ; Horswell S; Math M; Larkin J; Endesfelder D; Gronroos E; Martinez P; Matthews N; Stewart A; Tarpey P; Varela I; Phillimore B; Begum S; McDonald NQ; Butler A; Jones D; Raine K; Latimer C; Santos CR; Nohadani M; Eklund AC; Spencer-Dene B; Clark G; Pickering L; Stamp G; Gore M; Szallasi Z; Downward J; Futreal PA; Swanton C
N Engl J Med; 2012 Mar; 366(10):883-892. PubMed ID: 22397650
[TBL] [Abstract][Full Text] [Related]
2. Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Tannock IF
Eur Urol; 2014 Apr; 65(4):846-7. PubMed ID: 24559903
[No Abstract] [Full Text] [Related]
3. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
Turajlic S; Xu H; Litchfield K; Rowan A; Horswell S; Chambers T; O'Brien T; Lopez JI; Watkins TBK; Nicol D; Stares M; Challacombe B; Hazell S; Chandra A; Mitchell TJ; Au L; Eichler-Jonsson C; Jabbar F; Soultati A; Chowdhury S; Rudman S; Lynch J; Fernando A; Stamp G; Nye E; Stewart A; Xing W; Smith JC; Escudero M; Huffman A; Matthews N; Elgar G; Phillimore B; Costa M; Begum S; Ward S; Salm M; Boeing S; Fisher R; Spain L; Navas C; Grönroos E; Hobor S; Sharma S; Aurangzeb I; Lall S; Polson A; Varia M; Horsfield C; Fotiadis N; Pickering L; Schwarz RF; Silva B; Herrero J; Luscombe NM; Jamal-Hanjani M; Rosenthal R; Birkbak NJ; Wilson GA; Pipek O; Ribli D; Krzystanek M; Csabai I; Szallasi Z; Gore M; McGranahan N; Van Loo P; Campbell P; Larkin J; Swanton C;
Cell; 2018 Apr; 173(3):595-610.e11. PubMed ID: 29656894
[TBL] [Abstract][Full Text] [Related]
4. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.
Sankin A; Hakimi AA; Mikkilineni N; Ostrovnaya I; Silk MT; Liang Y; Mano R; Chevinsky M; Motzer RJ; Solomon SB; Cheng EH; Durack JC; Coleman JA; Russo P; Hsieh JJ
Cancer Med; 2014 Dec; 3(6):1485-92. PubMed ID: 25124064
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
[TBL] [Abstract][Full Text] [Related]
6. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
7. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
Gerlinger M; Horswell S; Larkin J; Rowan AJ; Salm MP; Varela I; Fisher R; McGranahan N; Matthews N; Santos CR; Martinez P; Phillimore B; Begum S; Rabinowitz A; Spencer-Dene B; Gulati S; Bates PA; Stamp G; Pickering L; Gore M; Nicol DL; Hazell S; Futreal PA; Stewart A; Swanton C
Nat Genet; 2014 Mar; 46(3):225-233. PubMed ID: 24487277
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
9. Re: intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Logothetis CJ
Eur Urol; 2013 Jul; 64(1):170. PubMed ID: 23746321
[No Abstract] [Full Text] [Related]
10. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
[TBL] [Abstract][Full Text] [Related]
11. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
[TBL] [Abstract][Full Text] [Related]
12. Parallel evolution of tumour subclones mimics diversity between tumours.
Martinez P; Birkbak NJ; Gerlinger M; McGranahan N; Burrell RA; Rowan AJ; Joshi T; Fisher R; Larkin J; Szallasi Z; Swanton C
J Pathol; 2013 Aug; 230(4):356-64. PubMed ID: 23716380
[TBL] [Abstract][Full Text] [Related]
13. Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract][Full Text] [Related]
14. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
[TBL] [Abstract][Full Text] [Related]
15. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
[TBL] [Abstract][Full Text] [Related]
16. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
[TBL] [Abstract][Full Text] [Related]
17. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
[TBL] [Abstract][Full Text] [Related]
18. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
[TBL] [Abstract][Full Text] [Related]
19. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Hsieh JJ; Manley BJ; Khan N; Gao J; Carlo MI; Cheng EH
Semin Cell Dev Biol; 2017 Apr; 64():98-106. PubMed ID: 27615548
[TBL] [Abstract][Full Text] [Related]
20. Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine.
Röcken C; Amallraja A; Halske C; Opasic L; Traulsen A; Behrens HM; Krüger S; Liu A; Haag J; Egberts JH; Rosenstiel P; Meißner T
Genome Med; 2021 Nov; 13(1):177. PubMed ID: 34749812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
